07 1月 2025 by admin in UncategorizedComments Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe
07 1月 2025 by admin in UncategorizedComments Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
06 1月 2025 by admin in UncategorizedComments Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
06 1月 2025 by admin in UncategorizedComments Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
19 12月 2024 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
18 12月 2024 by admin in UncategorizedComments Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
10 12月 2024 by admin in UncategorizedComments NextCure Announces Acceptance of IND Application for LNCB74
26 11月 2024 by admin in UncategorizedComments Oricell Therapeutics Receives China NMPA IND Clearance for MSLN/Claudin 18.2 Dual CAR-T Therapy for Solid Tumors
26 11月 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
20 11月 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director
19 11月 2024 by admin in UncategorizedComments Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
18 11月 2024 by admin in UncategorizedComments Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
12 11月 2024 by admin in UncategorizedComments Zenas BioPharma Completes Targeted Enrolment of the Phase 3 INDIGO Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) in Immunoglobulin G4-Related Disease (IgG4-RD)
12 11月 2024 by admin in UncategorizedComments Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
10 11月 2024 by admin in UncategorizedComments Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
23 10月 2024 by admin in UncategorizedComments Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
16 10月 2024 by admin in UncategorizedComments Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
30 9月 2024 by admin in UncategorizedComments Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
18 9月 2024 by admin in UncategorizedComments Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
10 9月 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces Formation of Scientific Advisory Board
03 9月 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer
20 8月 2024 by admin in UncategorizedComments 国际著名骨髓瘤专家 Kenneth C. Anderson 教授和 Shaji Kumar 教授加入原 启生物科学顾问委员会
19 8月 2024 by admin in UncategorizedComments Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
08 8月 2024 by admin in UncategorizedComments Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
15 7月 2024 by admin in UncategorizedComments Eluminex Biosciences Announces First Patient Dosed in the Phase 1b LOTUS Trial of the Novel Trispecific Fusion Antibody EB-105 in Diabetic Macular Edema (DME)
09 7月 2024 by admin in UncategorizedComments nterius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
01 7月 2024 by admin in UncategorizedComments Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer July 1, 2024
15 5月 2024 by admin in UncategorizedComments Sail Biomedicines Appoints Clinical and Scientific Leader Dr. Wendy Chung to Its Board
15 5月 2024 by admin in UncategorizedComments Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
13 5月 2024 by admin in UncategorizedComments RareStone Group Announces Appointment of Andy Zhang and Hardy Huan as Co-CEOs
07 5月 2024 by admin in UncategorizedComments Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
06 5月 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
26 4月 2024 by admin in UncategorizedComments Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis
